Tag: sorafenib

1. Enzalutamide along with androgen-deprivation therapy was shown to significantly increase median overall survival among men with non-metastatic, castration-resistant prostate cancer. 2. Adverse events for enzalutamide and androgen-deprivation therapy were shown to be consistent with the established safety profile of enzalutamide. Evidence Rating Level: 1 (Excellent) Study Rundown: Enzalutamide is an approved...
1. Combination treatment of atezolizumab and bevacizumab was shown to significantly increase overall survival and progression-free survival outcomes in patients with advanced unresectable hepatocellular carcinoma. 2. Patients treated with the combinatorial treatment of atezolizumab and bevacizumab were shown to experience serious toxic side effects. Evidence Rating Level: 1 (Excellent) Study Rundown: Hepatocellular...
1. After 2 years of treatment with sorafenib, patients with desmoid tumors had significantly increased progression-free survival rates compared to patients randomized to a placebo treatment. 2. Adverse effects most commonly reported by patients in the sorafenib group included rash and fatigue. Evidence Rating Level: 1 (Excellent)       Study Rundown: Desmoid tumors, also known...
In this section, we highlight the key high-impact studies, updates, and analyses published in medicine during the past week. Effect of Erythropoietin and Transfusion Threshold on Neurological Recovery After Traumatic Brain Injury Patients with traumatic brain injury (TBI) commonly develop anemia, which can cause secondary injury and worsen neurological outcomes. Erythropoietin has...
1. Compared to placebo, treatment with everolimus did not improve survival in patients with advanced hepatocellular carcinoma (HCC) who had previously failed sorafenib treatment.  2. Compared to placebo, everolimus treatment did not delay time to disease progression but did improve the disease control rate.  Evidence Rating Level: 1 (Excellent)    ...